Beckman Institute, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America.
PLoS Comput Biol. 2010 Sep 23;6(9):e1000939. doi: 10.1371/journal.pcbi.1000939.
Oseltamivir (Tamiflu) is currently the frontline antiviral drug employed to fight the flu virus in infected individuals by inhibiting neuraminidase, a flu protein responsible for the release of newly synthesized virions. However, oseltamivir resistance has become a critical problem due to rapid mutation of the flu virus. Unfortunately, how mutations actually confer drug resistance is not well understood. In this study, we employ molecular dynamics (MD) and steered molecular dynamics (SMD) simulations, as well as graphics processing unit (GPU)-accelerated electrostatic mapping, to uncover the mechanism behind point mutation induced oseltamivir-resistance in both H5N1 "avian" and H1N1pdm "swine" flu N1-subtype neuraminidases. The simulations reveal an electrostatic binding funnel that plays a key role in directing oseltamivir into and out of its binding site on N1 neuraminidase. The binding pathway for oseltamivir suggests how mutations disrupt drug binding and how new drugs may circumvent the resistance mechanisms.
奥司他韦(达菲)是目前用于治疗流感病毒感染患者的一线抗病毒药物,通过抑制神经氨酸酶发挥作用,神经氨酸酶是一种流感蛋白,负责释放新合成的病毒颗粒。然而,由于流感病毒的快速突变,奥司他韦耐药性已成为一个关键问题。不幸的是,突变如何实际赋予药物耐药性尚不清楚。在这项研究中,我们采用分子动力学(MD)和导向分子动力学(SMD)模拟以及图形处理单元(GPU)加速静电映射,揭示了 H5N1“禽流感”和 H1N1pdm“猪流感”N1 亚型神经氨酸酶中由点突变引起的奥司他韦耐药性的机制。模拟揭示了一个静电结合漏斗,它在引导奥司他韦进入和离开 N1 神经氨酸酶的结合位点方面起着关键作用。奥司他韦的结合途径表明突变如何破坏药物结合,以及新药物如何规避耐药机制。